Response assessment by combined PET-CT scan versus ct scan alone using RECIST in patients with locally advanced head and neck cancer treated with chemoradiotherapy

V. A. Passero, B. F. Branstetter, Y. Shuai, D. E. Heron, M. K. Gibson, S. Y. Lai, S. W. Kim, J. R. Grandis, R. L. Ferris, J. T. Johnson, A. Argiris

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Purpose: RECIST have limitations when applied to potentially curable locally advanced squamous cell carcinoma of the head and neck (SCCHN). [18F]fluorodeoxyglucose-positron emission tomography (PET) scan may be useful in assessing treatment response and predicting patient outcome. Patients and methods: We studied patients with previously untreated stages III-IVb SCCHN treated with primary concurrent chemoradiotherapy on five prospective clinical trials. Response was assessed by clinical exam, computed tomography (CT), and PET portions of combined PET-CT scan ∼8 weeks after completion of chemoradiotherapy.Results: Fifty-three patients were analyzed. Complete response (CR) was demonstrated in 42 patients (79%) by clinical exam, 15 (28%) by CT, and 27 (51%) by PET. CR as assessed by PET, but not as assessed by clinical exam or CT using RECIST, correlated significantly with progression-free status (PFS) (P < 0.0001). The 2-year PFS for patients with CR and without CR by PET was 93% and 48%, respectively (P = 0.0002).Conclusions: A negative PET scan on combined PET-CT after chemoradiotherapy is a powerful predictor of outcome in patients receiving curative chemoradiotherapy for SCCHN. PET-CT is indicated for response evaluation in this setting to improve the accuracy of post-treatment assessment by CT.

Original languageEnglish (US)
Pages (from-to)2278-2283
Number of pages6
JournalAnnals of Oncology
Volume21
Issue number11
DOIs
StatePublished - Nov 2010
Externally publishedYes

Fingerprint

Chemoradiotherapy
Head and Neck Neoplasms
Positron-Emission Tomography
Tomography
Fluorodeoxyglucose F18
Positron Emission Tomography Computed Tomography
Response Evaluation Criteria in Solid Tumors
Clinical Trials
Therapeutics
Carcinoma, squamous cell of head and neck

Keywords

  • Chemoradiotherapy
  • Head and neck cancer
  • Objective response
  • PET-CT
  • RECIST

ASJC Scopus subject areas

  • Oncology
  • Hematology

Cite this

Response assessment by combined PET-CT scan versus ct scan alone using RECIST in patients with locally advanced head and neck cancer treated with chemoradiotherapy. / Passero, V. A.; Branstetter, B. F.; Shuai, Y.; Heron, D. E.; Gibson, M. K.; Lai, S. Y.; Kim, S. W.; Grandis, J. R.; Ferris, R. L.; Johnson, J. T.; Argiris, A.

In: Annals of Oncology, Vol. 21, No. 11, 11.2010, p. 2278-2283.

Research output: Contribution to journalArticle

Passero, VA, Branstetter, BF, Shuai, Y, Heron, DE, Gibson, MK, Lai, SY, Kim, SW, Grandis, JR, Ferris, RL, Johnson, JT & Argiris, A 2010, 'Response assessment by combined PET-CT scan versus ct scan alone using RECIST in patients with locally advanced head and neck cancer treated with chemoradiotherapy', Annals of Oncology, vol. 21, no. 11, pp. 2278-2283. https://doi.org/10.1093/annonc/mdq226
Passero, V. A. ; Branstetter, B. F. ; Shuai, Y. ; Heron, D. E. ; Gibson, M. K. ; Lai, S. Y. ; Kim, S. W. ; Grandis, J. R. ; Ferris, R. L. ; Johnson, J. T. ; Argiris, A. / Response assessment by combined PET-CT scan versus ct scan alone using RECIST in patients with locally advanced head and neck cancer treated with chemoradiotherapy. In: Annals of Oncology. 2010 ; Vol. 21, No. 11. pp. 2278-2283.
@article{f1ca762a58bb44c0ab10157c509e7ad6,
title = "Response assessment by combined PET-CT scan versus ct scan alone using RECIST in patients with locally advanced head and neck cancer treated with chemoradiotherapy",
abstract = "Purpose: RECIST have limitations when applied to potentially curable locally advanced squamous cell carcinoma of the head and neck (SCCHN). [18F]fluorodeoxyglucose-positron emission tomography (PET) scan may be useful in assessing treatment response and predicting patient outcome. Patients and methods: We studied patients with previously untreated stages III-IVb SCCHN treated with primary concurrent chemoradiotherapy on five prospective clinical trials. Response was assessed by clinical exam, computed tomography (CT), and PET portions of combined PET-CT scan ∼8 weeks after completion of chemoradiotherapy.Results: Fifty-three patients were analyzed. Complete response (CR) was demonstrated in 42 patients (79{\%}) by clinical exam, 15 (28{\%}) by CT, and 27 (51{\%}) by PET. CR as assessed by PET, but not as assessed by clinical exam or CT using RECIST, correlated significantly with progression-free status (PFS) (P < 0.0001). The 2-year PFS for patients with CR and without CR by PET was 93{\%} and 48{\%}, respectively (P = 0.0002).Conclusions: A negative PET scan on combined PET-CT after chemoradiotherapy is a powerful predictor of outcome in patients receiving curative chemoradiotherapy for SCCHN. PET-CT is indicated for response evaluation in this setting to improve the accuracy of post-treatment assessment by CT.",
keywords = "Chemoradiotherapy, Head and neck cancer, Objective response, PET-CT, RECIST",
author = "Passero, {V. A.} and Branstetter, {B. F.} and Y. Shuai and Heron, {D. E.} and Gibson, {M. K.} and Lai, {S. Y.} and Kim, {S. W.} and Grandis, {J. R.} and Ferris, {R. L.} and Johnson, {J. T.} and A. Argiris",
year = "2010",
month = "11",
doi = "10.1093/annonc/mdq226",
language = "English (US)",
volume = "21",
pages = "2278--2283",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "11",

}

TY - JOUR

T1 - Response assessment by combined PET-CT scan versus ct scan alone using RECIST in patients with locally advanced head and neck cancer treated with chemoradiotherapy

AU - Passero, V. A.

AU - Branstetter, B. F.

AU - Shuai, Y.

AU - Heron, D. E.

AU - Gibson, M. K.

AU - Lai, S. Y.

AU - Kim, S. W.

AU - Grandis, J. R.

AU - Ferris, R. L.

AU - Johnson, J. T.

AU - Argiris, A.

PY - 2010/11

Y1 - 2010/11

N2 - Purpose: RECIST have limitations when applied to potentially curable locally advanced squamous cell carcinoma of the head and neck (SCCHN). [18F]fluorodeoxyglucose-positron emission tomography (PET) scan may be useful in assessing treatment response and predicting patient outcome. Patients and methods: We studied patients with previously untreated stages III-IVb SCCHN treated with primary concurrent chemoradiotherapy on five prospective clinical trials. Response was assessed by clinical exam, computed tomography (CT), and PET portions of combined PET-CT scan ∼8 weeks after completion of chemoradiotherapy.Results: Fifty-three patients were analyzed. Complete response (CR) was demonstrated in 42 patients (79%) by clinical exam, 15 (28%) by CT, and 27 (51%) by PET. CR as assessed by PET, but not as assessed by clinical exam or CT using RECIST, correlated significantly with progression-free status (PFS) (P < 0.0001). The 2-year PFS for patients with CR and without CR by PET was 93% and 48%, respectively (P = 0.0002).Conclusions: A negative PET scan on combined PET-CT after chemoradiotherapy is a powerful predictor of outcome in patients receiving curative chemoradiotherapy for SCCHN. PET-CT is indicated for response evaluation in this setting to improve the accuracy of post-treatment assessment by CT.

AB - Purpose: RECIST have limitations when applied to potentially curable locally advanced squamous cell carcinoma of the head and neck (SCCHN). [18F]fluorodeoxyglucose-positron emission tomography (PET) scan may be useful in assessing treatment response and predicting patient outcome. Patients and methods: We studied patients with previously untreated stages III-IVb SCCHN treated with primary concurrent chemoradiotherapy on five prospective clinical trials. Response was assessed by clinical exam, computed tomography (CT), and PET portions of combined PET-CT scan ∼8 weeks after completion of chemoradiotherapy.Results: Fifty-three patients were analyzed. Complete response (CR) was demonstrated in 42 patients (79%) by clinical exam, 15 (28%) by CT, and 27 (51%) by PET. CR as assessed by PET, but not as assessed by clinical exam or CT using RECIST, correlated significantly with progression-free status (PFS) (P < 0.0001). The 2-year PFS for patients with CR and without CR by PET was 93% and 48%, respectively (P = 0.0002).Conclusions: A negative PET scan on combined PET-CT after chemoradiotherapy is a powerful predictor of outcome in patients receiving curative chemoradiotherapy for SCCHN. PET-CT is indicated for response evaluation in this setting to improve the accuracy of post-treatment assessment by CT.

KW - Chemoradiotherapy

KW - Head and neck cancer

KW - Objective response

KW - PET-CT

KW - RECIST

UR - http://www.scopus.com/inward/record.url?scp=77958481883&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77958481883&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdq226

DO - 10.1093/annonc/mdq226

M3 - Article

C2 - 20430907

AN - SCOPUS:77958481883

VL - 21

SP - 2278

EP - 2283

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 11

ER -